Last updated: April 25, 2026
What is the product baseline for “Carnitor”?
“Carnitor” is the brand name of levocarnitine (pharmacologic class: carnitine replacement). The supplier landscape depends on whether the inquiry targets:
- Active pharmaceutical ingredient (API) suppliers for levocarnitine, or
- Finished-dose suppliers of Carnitor (which is governed by the brand owner’s commercial supply chain and labeled manufacturer on pack).
The market uses multiple levocarnitine salt forms (notably levocarnitine base and levocarnitine injection/solution depending on jurisdiction). Any supplier listing must align to the intended dosage form and salt form.
Which suppliers typically appear in the levocarnitine API supply chain?
Levocarnitine is a bulk chemical ingredient with broad industrial availability. In practice, API sourcing is commonly handled via:
- Dedicated fine-chemical and nutraceutical ingredient manufacturers that produce levocarnitine (often under GMP for pharma use), and
- Contract manufacturers that produce the finished sterile or oral dosage form for the brand holder.
In the absence of pack-level labeling or jurisdiction-specific regulatory listings, the most reliable “supplier” definition for Carnitor is the finished product manufacturer(s) shown on the label and the API manufacturer(s) disclosed in regulatory dossiers.
How do you identify the correct “Carnitor” supplier from primary records?
Use three hard reference points:
1) Label / pack information
For each strength and dosage form, Carnitor outer cartons and inserts list the manufacturing site (and sometimes the marketing authorization holder). This defines the finished-drug supplier that matters for:
- sourcing finished product,
- compliance due diligence, and
- cold-chain or sterile manufacturing controls (for injection forms).
2) Marketing authorization dossiers (jurisdictional)
Regulators publish or summarize:
- the marketing authorization holder, and
- manufacturing sites for product and sometimes API.
3) API traceability for levocarnitine
APIs are tracked in GMP supply chains via:
- supplier release documents (CoA),
- DMF/CEP references (where applicable), and
- batch traceability within quality systems.
Supplier roster: What can be stated with certainty from general market structure
Because “Carnitor” is a branded levocarnitine product and the question does not specify:
- country,
- dosage form (oral vs injection),
- strength, or
- whether “supplier” means API or finished product,
a definitive named supplier list cannot be produced without risking inaccuracies. Under a strict patent-analysis standard, only supplier identities tied to label or regulatory filings can be asserted as “Carnitor suppliers.”
Operationally usable framework (decision-ready)
Below is the correct way to map suppliers once the dosage form and jurisdiction are pinned down (so the supplier names match the marketed product, not generic levocarnitine).
A) Finished product supplier (Carnitor-specific)
Collect, for each dosage form:
- manufacturing site listed on package/leaflet,
- batch manufacturing location,
- marketing authorization holder.
This is the “supplier” that procurement should contract with if buying finished product.
B) API supplier (levocarnitine-specific)
Collect:
- API manufacturer(s) listed for levocarnitine substance in the dossier,
- any CEP/DMF numbers tied to the substance,
- GMP site addresses.
This supports:
- API qualification,
- substitution risk assessment,
- IP and regulatory alignment for levocarnitine salt form.
Tables: What should be filled in from label/regulatory records
Table 1. Finished product supplier mapping (per dosage form)
| Dosage form |
Strength |
Jurisdiction |
Label manufacturer / site |
Notes (sterile/oral) |
| Injection |
(per market) |
(country) |
(from label) |
sterile manufacturing constraints |
| Oral solution |
(per market) |
(country) |
(from label) |
preservative and container controls |
| Tablets |
(per market) |
(country) |
(from label) |
excipient and dissolution controls |
Table 2. API supplier mapping (levocarnitine substance)
| Levocarnitine form |
Jurisdiction |
Regulatory disclosure |
API manufacturer / site |
Evidence (CEP/DMF/batch) |
| Levocarnitine base |
(country) |
substance section |
(from dossier) |
(from filing references) |
| Levocarnitine salt (as marketed) |
(country) |
substance section |
(from dossier) |
(from filing references) |
Key Takeaways
- “Carnitor supplier” must be defined as either finished product manufacturer or levocarnitine API supplier; the supplier names differ.
- The only defensible approach for a correct named supplier list is label-based (finished product) and dossier-based (API) identification by dosage form, strength, and jurisdiction.
- Without those anchors, any named supplier list would risk mismatching the marketed product’s actual manufacturing site or salt/form.
FAQs
1) Are Carnitor suppliers the same across countries?
No. Manufacturing sites and label “manufacturer” fields vary by jurisdiction even when the active ingredient is levocarnitine.
2) Does “Carnitor supplier” mean API manufacturer or finished-goods manufacturer?
Procurement and compliance typically use finished product manufacturer from the package. Patent and chemistry sourcing often uses the API manufacturer disclosed in regulatory filings.
3) Is levocarnitine always the same salt form in Carnitor?
Carnitor products are levocarnitine-based, but marketed formulations can differ by dosage form and salt/form conventions in different regions.
4) Where is the most audit-ready supplier evidence for Carnitor?
The most direct evidence is the label/leaflet manufacturing site for the specific product and batch, plus the regulatory dossier substance/product sections for API and manufacturing disclosures.
5) Can one list generic levocarnitine API manufacturers and call them “Carnitor suppliers”?
No. Generic ingredient manufacturers may supply levocarnitine, but they are not automatically the Carnitor-labeled manufacturing suppliers for a specific market.
References
- FDA Orange Book. United States Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via https://www.accessdata.fda.gov/scripts/cder/daf/ ).
- European Medicines Agency. European public assessment reports (EPAR) and product information for levocarnitine-containing products. (Accessed via https://www.ema.europa.eu/ ).
- European Commission. Community register of medicinal products and associated documentation links. (Accessed via https://ec.europa.eu/health/documents/community-register_en ).
